Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01-AE in Hong Kong by genotyping and phenotyping methods

AIDS Research and Human Retroviruses

Volumn 29, Issue 8, 2013, Pages 1123-1128

  To, Sabrina Wai Chi ^a   Chen, Jonathan Hon Kwan ^a   Wong, Ka Hing ^b   Chan, Kenny Chi Wai ^b   Chen, Zhiwei ^a   Yam, Wing Cheong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST;

ALGORITHM; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; GENOTYPE; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; VIRAL TROPISM; VIRUS LOAD;

GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HONG KONG; HUMANS; PHENOTYPE; POLYMERASE CHAIN REACTION; POSITION-SPECIFIC SCORING MATRICES; PREVALENCE; VIRAL TROPISM;

EID: 84880557730     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0067     Document Type: Article

References (40)

1. Berger EA, Murphy PM, and Farber JM. Chemokine receptors as HIV-1 coreceptors. Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
2. Dorr P, Westby M, Dobbs S, et al.. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-4732.
3. Vandekerckhove LP, Wensing AM, Kaiser R, et al.. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11(5):394-407.
4. Coakley E, Petropoulos CJ, and Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005;18(1):9-15.
5. Whitcomb JM, Huang W, Fransen S, et al.. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51(2):566-575.
6. Su Z, Gulick RM, Krambrink A, et al.. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay. Reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009;200(11). 1724-1728.
7. Raymond S, Delobel P, Mavigner M, et al.. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010;47(2):126-130.
8. Lin NH, Negusse DM, Beroukhim R, et al.. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods 2010; 169(1):39-46.
9. Lengauer T, Sander O, Sierra S, Thielen A, and Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007;25(12):1407-1410.
10. Sing T, Low AJ, Beerenwinkel N, et al.. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antiviral Ther 2007;12(7):1097-1106.
11. Briggs DR, Tuttle DL, Sleasman JW, and Goodenow MM. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 22 2000;14(18):2937-2939.
12. Jensen MA, Li FS, van 't Wout AB, et al.. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003;77(24). 13376-13388.
13. Sander O, Sing T, Sommer I, et al.. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 2007;3(3):e58.
14. Pillai S, Good B, Richman D, and Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003;19(2):145-149.
15. Raymond S, Delobel P, Mavigner M, et al.. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22(14):F11-16.
16. Seclen E, Garrido C, Gonzalez Mdel M, et al.. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral- experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010;65(7). 1486-1492.
17. Harrigan PR, Chui CKS, Brumme ZL, et al.. A simple screening approach to reduce B.*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007;44(11):1503-1508.
18. Goulder PJR, Kiepiela P, Leslie AJ, et al.. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004;432(7018):769-774.
19. Raymond S, Delobel P, Mavigner M, et al.. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009;47(7):2292-2294.
20. Hemelaar J, Gouws E, Ghys PD, and Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25(5):679-689.
21. Zhang C, Xu S, Wei J, and Guo H. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops. Implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis 2009;13(5). e212-216.
22. Pantaleo G, Harari A, Cellerai C, et al.. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007;104(41). 16233-16238.
23. Frange P, Chaix ML, Raymond S, et al.. Low frequency of CXCR4-using viruses in patients at the time of primary nonsubtype-B HIV-1 infection. J Clin Microbiol 2010;48(10). 3487-3491.
24. KY. N, KK. C, P. K, et al.. High prevalence of CXCR4 usage among treatment-naive CRF01-AE and CRF51-01B-infected HIV-1 subjects in Singapore. BMC Infect Dis 2013;13(1):90.
25. The Special Preventive Programme and the Social Hygiene Service of the Department of Health TGotHKSAR. HIV/ADIS Quarterly Statistics. www.info.gov.hk/aids/english/surveillance/latest-stat.htm.
26. Chen JH, Wong KH, Chan K, et al.. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol 2007;39(2):125-131.
27. de Oliveira T, Deforche K, Cassol S, et al.. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21(19):3797-3800.
28. Symons J, Vandekerckhove L, Paredes R, et al.. Impact of triplicate testing on genotypic HIV-1 tropism prediction in routine clinical practice. Clin Microbiol Infect 2011;18(6):1-7.
29. McGovern RA, Thielen A, Mo T, et al.. Population-based V3 genotypic tropism assay. A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010;24(16):2517-2525.
30. Staden R, Beal KF, and Bonfield JK. The Staden package, 1998. Methods Mol Biol 2000;132:115-130.
31. Harrigan PR, McGovern RA, Dong W, et al.. Screening for HIV tropism using population based V3 genotypic analysis. A retrospective virologic outcome analysis using stored plasma screening samples from the MOTIVATE studies of maraviroc in treatment experienced patients [abstract]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009.
32. McGovern RA, Dong W, Zhong X, et al.. Population-based sequencing of the V3-loop is comparable to the Enhanced Sensitivity Trofile Assay in predicting virologic response to maraviroc of treatment-naive patients in the MERIT trial [abstract]. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
33. Low AJ, Dong W, Chan D, et al.. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007;21(14):F17-24.
34. Hammond E, Mamotte C, Nolan D, and Mallal S. HLAB* 5701 typing. Evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens 2007;70(1). 58-61.
35. Mallal S, Lucas A, and Nolan D. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007;59(4):591-593.
36. Hammond E, Almeida CA, Momotte C, et al.. External quality assessment of HLA-B*5701 reporting. An international multicentre survey. Antiviral Ther 2007;12(7):1027-1032.
37. Andersson J, Fehniger TE, Patterson BK, et al.. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998;12(11):F123-129.
38. Mallal S, Martin AM, Nolan D, et al.. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101(12):4180-4185.
39. Bugawan T, Isoda W, Mano C, et al.. Hla-B*5701 Taqman assay for abacavir sensitivity; application to Predict-1 Trials. Hum Immunol 2008;69:S89-S89.
40. Yu X, Yuan L, Huang Y, et al.. Susceptibility of HIV-1 subtypes B', CRF07-BC and CRF01-AE that are predominantly circulating in China to HIV-1 entry inhibitors. PloS One 2011; 6(3):e17605. Government